
IZQVD
Healthcare · Drug Manufacturers - Specialty & Generic · $2.72B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 27, 2022 | Before the open | — | 0.28 | — |
| Jul 28, 2022 | Before the open | — | 0.34 | — |
| Apr 28, 2022 | Before the open | — | 0.28 | — |
| Feb 16, 2022 | Before the open | — | 0.25 | — |
| Oct 28, 2021 | Before the open | — | 0.15 | — |
| Jul 29, 2021 | Before the open | — | 0.40 | — |
| Apr 29, 2021 | Before the open | — | 0.51 | — |
| Feb 18, 2021 | Before the open | — | 0.15 | — |
| Oct 29, 2020 | Before the open | — | 0.10 | — |
| Jul 30, 2020 | Before the open | — | 0.02 | — |
| May 14, 2020 | Before the open | — | -1.11 | — |
| Feb 13, 2020 | Before the open | — | -0.38 | — |
| Oct 31, 2019 | Before the open | — | 0.30 | — |
| Jul 31, 2019 |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE…
| Before the open |
| — |
| 0.50 |
| — |
| May 2, 2019 | Before the open | — | 0.44 | — |
| Feb 14, 2019 | Before the open | 0.07 | 0.09 | +28.6% |
| Nov 1, 2018 | Before the open | 0.05 | 0.12 | +140.0% |
| Jul 25, 2018 | Before the open | 0.09 | 0.09 | 0.0% |
| May 2, 2018 | Before the open | — | 0.62 | — |
| Feb 15, 2018 | Before the open | 0.07 | 0.07 | 0.0% |